Savolitinib - CAS 1313725-88-0
Catalog number: B0084-462234
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H15N9
Molecular Weight:
345.37
COA:
Inquire
Targets:
c-Met/HGFR
Description:
Savolitinib is a tyrosine kinase inhibitor with potential anticancer activity.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462234 50 mg $599 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
Solid powder
Synonyms:
Volitinib; HMPL 504; HMPL0-504; HMPL504; AZD 6094; AZD 6094; AZD-6094; Savolitinib.
MSDS:
Inquire
InChIKey:
XYDNMOZJKOGZLS-NSHDSACASA-N
InChI:
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
Canonical SMILES:
CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
Current Developer:
Hutchison Medipharma Limited
1.The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG1, Barry ER1, Jones RD2, Henry RE1, Frigault MM1, Beran G3, Linsenmayer D1, Hattersley M1, Smith A2, Wilson J2, Cairo S4, Déas O4, Nicolle D4, Adam A1, Zinda M1, Reimer C1, Fawell SE1, Clark EA1, D'Cruz CM5. Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.
PURPOSE: Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for patients with nonlocalized disease. The HGF receptor MET plays a central role in PRCC and aberrations, either through mutation, copy number gain, or trisomy of chromosome 7 occurring in the majority of cases. The development of effective therapies in PRCC has been hampered in part by a lack of available preclinical models. We determined the pharmacodynamic and antitumor response of the selective MET inhibitor AZD6094 in two PRCC patient-derived xenograft (PDX) models.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related c-Met/HGFR Products


CAS 1001917-37-8 MK-8033

MK-8033
(CAS: 1001917-37-8)

MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

SCR-1481B1
(CAS: 1174161-86-4)

SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...

CAS 477575-56-7 PHA665752

PHA665752
(CAS: 477575-56-7)

PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling c-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL....

CAS 917879-39-1 MK-2461

MK-2461
(CAS: 917879-39-1)

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro phosphorylation of a peptide substrate recognized by w...

CAS 943540-75-8 JNJ-38877605

JNJ-38877605
(CAS: 943540-75-8)

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

CAS 956906-93-7 PF-04217903 methanesulfonate

PF-04217903 methanesulfonate
(CAS: 956906-93-7)

PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed ...

CAS 1002304-34-8 AMG208

AMG208
(CAS: 1002304-34-8)

AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...

CAS 1029712-80-8 Capmatinib

Capmatinib
(CAS: 1029712-80-8)

Capmatinib, also known as INCB28060 and INC280,  is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...

Chemical Structure

CAS 1313725-88-0 Savolitinib

Quick Inquiry

Verification code

Featured Items